One ingredient can have several licensed uses
A GLP-1 medicine may be authorised for type 2 diabetes, weight management or another named use. The product information sets the indication, the age group and the conditions of use. A familiar brand name will not tell you all of these.
Diabetes care usually focuses on glucose control and preventing complications. Weight management looks at weight-related health risks, physical function and other goals you agree with your clinician. If you live with both conditions, you may gain in more than one way. Your clinician still has to pick a suitable product and fit the plan around your other treatments.
Licence, NHS guidance and funding are separate decisions
A marketing authorisation means the regulator has assessed a medicine for named uses. The NHS will not fund it for everyone within the licence. NICE recommendations, national rollout plans and local services can narrow who gets it in practice. Scotland, Wales and Northern Ireland make and deliver their own decisions.
You can also pay for a private prescription. Paying does not skip the clinical assessment. The provider must still confirm treatment is suitable and safe for you. A website saying a medicine is available does not mean you are eligible or will receive a prescription.
Off-label prescribing needs a clear reason
Off-label means a licensed medicine is prescribed outside one of the terms of its authorisation. In the right circumstances this is legitimate clinical practice. Some off-label uses have far stronger evidence than others. Off-label prescribing also differs from buying an unlicensed product from an unknown seller.
If your proposed use is off-label, ask why your clinician recommends it, what evidence supports it, which licensed options they considered and who will monitor you. Never work out your dose from someone else's prescription. This matters most when a diabetes brand and an obesity brand share an ingredient.
Keep diabetes care and weight care linked
If you use insulin or other glucose-lowering medicines, you may need extra monitoring or dose changes when a new treatment starts. Your prescribing team makes those changes. Losing weight is no reason to stop your diabetes care, eye checks or other follow-up.
Tell every clinician about privately supplied medicines as well as NHS prescriptions. Ask which service handles each part of your care: repeat prescriptions, blood tests, side-effect support and long-term review. A named owner for each task helps more than a general promise the two services work together. A named owner also stops double treatment, and gaps when one service changes.
Brands differ between countries
A brand can have a different use or formulation in another country. A US article about a weight-management brand may not match the UK licence for the same name. Check the UK licence before you rely on it.
You also cannot tell someone's diagnosis from the brand they mention online. When you read an international story, note the country, the publication date and the authorised use. This small check clears up a lot of confusion about eligibility, prescribing and why two people get different advice.
Sources
Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.
- MHRA: GLP-1 medicines for weight loss and diabetes gov.uk
- NICE NG246: Overweight and obesity management nice.org.uk
- NICE: A guide for prescribing medicines to manage overweight and obesity nice.org.uk
Spotted something out of date? Report a mistake.